{"resourceType":"CodeSystem","id":"IMMZ.D1","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This case-insensitive code system <code>http://smart.who.int/ig/smart-immunizations/CodeSystem/IMMZ.D1</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">DE80<a name=\"IMMZ.D1-DE80\"> </a></td><td>Dose 0 administered</td><td>Indicates if the client has received a birth dose and/or a zero dose</td></tr><tr><td style=\"white-space:nowrap\">DE95<a name=\"IMMZ.D1-DE95\"> </a></td><td>Booster dose administered</td><td>Indicates if the client has received a booster dose and/or a supplementary dose</td></tr><tr><td style=\"white-space:nowrap\">DE8<a name=\"IMMZ.D1-DE8\"> </a></td><td>Completed the primary vaccination series</td><td>Indicates if the client has completed the primary vaccination series of a product/antigen. If the client has not yet completed their primary series, it means they may be expected to receive more doses to complete their vaccination regimen for the respective product/antigen.</td></tr><tr><td style=\"white-space:nowrap\">DE81<a name=\"IMMZ.D1-DE81\"> </a></td><td>Date when primary vaccination series was completed</td><td>The date when the client completed the primary vaccination series (per product/antigen)</td></tr><tr><td style=\"white-space:nowrap\">DE10<a name=\"IMMZ.D1-DE10\"> </a></td><td>HIV status</td><td>The current human immunodeficiency virus (HIV) status of the client</td></tr><tr><td style=\"white-space:nowrap\">DE11<a name=\"IMMZ.D1-DE11\"> </a></td><td>HIV-positive</td><td>The client is known to be HIV positive</td></tr><tr><td style=\"white-space:nowrap\">DE12<a name=\"IMMZ.D1-DE12\"> </a></td><td>HIV-negative</td><td>The client is known to be HIV negative</td></tr><tr><td style=\"white-space:nowrap\">DE13<a name=\"IMMZ.D1-DE13\"> </a></td><td>Unknown</td><td>The client's HIV status is unknown</td></tr><tr><td style=\"white-space:nowrap\">DE15<a name=\"IMMZ.D1-DE15\"> </a></td><td>Preterm birth</td><td>The infant was preterm; the mother gave birth to the infant when gestational age was less than 37 weeks</td></tr><tr><td style=\"white-space:nowrap\">DE16<a name=\"IMMZ.D1-DE16\"> </a></td><td>Immunocompromised</td><td>The client is known to be immunocompromised. This means the client has a weakened immune system and having a reduced ability to fight infections and other diseases</td></tr><tr><td style=\"white-space:nowrap\">DE17<a name=\"IMMZ.D1-DE17\"> </a></td><td>Currently on ART</td><td>The client is currently receiving antiretroviral therapy (ART)</td></tr><tr><td style=\"white-space:nowrap\">DE84<a name=\"IMMZ.D1-DE84\"> </a></td><td>Type of TB infection test performed</td><td>The type of TB infection test performed</td></tr><tr><td style=\"white-space:nowrap\">DE85<a name=\"IMMZ.D1-DE85\"> </a></td><td>IGRA</td><td>Interferon-gamma release assay (IGRA)</td></tr><tr><td style=\"white-space:nowrap\">DE86<a name=\"IMMZ.D1-DE86\"> </a></td><td>TST</td><td>Tuberculin skin test (TST)</td></tr><tr><td style=\"white-space:nowrap\">DE87<a name=\"IMMZ.D1-DE87\"> </a></td><td>TB infection test result</td><td>Records the result of the TB infection test</td></tr><tr><td style=\"white-space:nowrap\">DE88<a name=\"IMMZ.D1-DE88\"> </a></td><td>Positive</td><td>Test result was positive</td></tr><tr><td style=\"white-space:nowrap\">DE89<a name=\"IMMZ.D1-DE89\"> </a></td><td>Negative</td><td>Test result was negative</td></tr><tr><td style=\"white-space:nowrap\">DE93<a name=\"IMMZ.D1-DE93\"> </a></td><td>Immunologically stable</td><td>The client is living with HIV and is immunologically stable with CD4 count or percentage above a minimum as defined in the HIV guidelines</td></tr><tr><td style=\"white-space:nowrap\">DE94<a name=\"IMMZ.D1-DE94\"> </a></td><td>Clinically well</td><td>The client is living with HIV and is clinically well, as defined in HIV guidelines and WHO clinical staging</td></tr><tr><td style=\"white-space:nowrap\">DE29<a name=\"IMMZ.D1-DE29\"> </a></td><td>Birth weight in grams</td><td>Represents the client's birth weight value measures in grams</td></tr><tr><td style=\"white-space:nowrap\">DE35<a name=\"IMMZ.D1-DE35\"> </a></td><td>Type of polio dose</td><td>The type of the polio vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE36<a name=\"IMMZ.D1-DE36\"> </a></td><td>IPV</td><td>Inactivated poliovirus vaccine (IPV)</td></tr><tr><td style=\"white-space:nowrap\">DE37<a name=\"IMMZ.D1-DE37\"> </a></td><td>bOPV</td><td>Bivalent oral poliovirus vaccine (bOPV)</td></tr><tr><td style=\"white-space:nowrap\">DE38<a name=\"IMMZ.D1-DE38\"> </a></td><td>Age in years when client received first DTP dose</td><td>The client's age in years when they received their first diphtheria-tetanus-pertussis (DTP) dose</td></tr><tr><td style=\"white-space:nowrap\">DE39<a name=\"IMMZ.D1-DE39\"> </a></td><td>Age in months when client received first Hib dose</td><td>The client's age in months when they received their first Haemophilus influenzae type b (Hib) dose</td></tr><tr><td style=\"white-space:nowrap\">DE92<a name=\"IMMZ.D1-DE92\"> </a></td><td>Severely immunosuppressed</td><td>The client is known to be severely immunocompromised or immunosuppressed</td></tr><tr><td style=\"white-space:nowrap\">DE49<a name=\"IMMZ.D1-DE49\"> </a></td><td>ART start date</td><td>The date on which the client started or restarted antiretroviral therapy (ART)</td></tr><tr><td style=\"white-space:nowrap\">DE96<a name=\"IMMZ.D1-DE96\"> </a></td><td>High risk of pneumococcal infection</td><td>The client is at high risk for pneumococcal infection because of underlying medical conditions (i.e. HIV infection or sickle-cell disease)</td></tr><tr><td style=\"white-space:nowrap\">DE52<a name=\"IMMZ.D1-DE52\"> </a></td><td>Type of JE dose</td><td>The type of Japanese encephalitis (JE) vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE53<a name=\"IMMZ.D1-DE53\"> </a></td><td>Inactivated Vero cell-derived vaccine</td><td>Inactivated Vero cell-derived Japanese encephalitis (JE) vaccine type</td></tr><tr><td style=\"white-space:nowrap\">DE54<a name=\"IMMZ.D1-DE54\"> </a></td><td>Live attenuated vaccine</td><td>Live attenuated Japanese encephalitis (JE) vaccine type</td></tr><tr><td style=\"white-space:nowrap\">DE55<a name=\"IMMZ.D1-DE55\"> </a></td><td>Live recombinant vaccine</td><td>Live recombinant Japanese encephalitis (JE) vaccine type</td></tr><tr><td style=\"white-space:nowrap\">DE56<a name=\"IMMZ.D1-DE56\"> </a></td><td>Type of TBE dose</td><td>The type of tick-borne encephalitis (TBE) vaccine dose administered</td></tr><tr><td style=\"white-space:nowrap\">DE57<a name=\"IMMZ.D1-DE57\"> </a></td><td>FSME-Immun</td><td>FSME-Immun vaccine product, which is an inactivated whole-virus vaccine for tick-borne encephalitis (TBE)</td></tr><tr><td style=\"white-space:nowrap\">DE58<a name=\"IMMZ.D1-DE58\"> </a></td><td>Encepur</td><td>Encepur vaccine product, which is an inactivated viral vaccine for tick-borne encephalitis (TBE)</td></tr><tr><td style=\"white-space:nowrap\">DE59<a name=\"IMMZ.D1-DE59\"> </a></td><td>TBE-Moscow</td><td>TBE-Moscow vaccine product, which is a vaccine for tick-borne encephalitis (TBE)</td></tr><tr><td style=\"white-space:nowrap\">DE60<a name=\"IMMZ.D1-DE60\"> </a></td><td>EnceVir</td><td>EnceVir vaccine product, which is a vaccine for tick-borne encephalitis (TBE)</td></tr><tr><td style=\"white-space:nowrap\">DE61<a name=\"IMMZ.D1-DE61\"> </a></td><td>Type of typhoid dose</td><td>The type of typhoid vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE62<a name=\"IMMZ.D1-DE62\"> </a></td><td>Typbar-TCV</td><td>Typbar-TCV vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE63<a name=\"IMMZ.D1-DE63\"> </a></td><td>ViPS</td><td>Vi polysaccharide (ViPS) vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE64<a name=\"IMMZ.D1-DE64\"> </a></td><td>Ty21a</td><td>Ty21a vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE65<a name=\"IMMZ.D1-DE65\"> </a></td><td>Type of cholera dose</td><td>The type of cholera vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE66<a name=\"IMMZ.D1-DE66\"> </a></td><td>WC vaccine</td><td>Killed whole cell (WC) only cholera vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE67<a name=\"IMMZ.D1-DE67\"> </a></td><td>WC-rBS vaccine</td><td>Vaccine contains a mixture of the recombinant B subunit (rBS) of cholera toxin plus killed whole cell (WC)</td></tr><tr><td style=\"white-space:nowrap\">DE68<a name=\"IMMZ.D1-DE68\"> </a></td><td>Type of meningococcal dose</td><td>The type of meningococcal vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE69<a name=\"IMMZ.D1-DE69\"> </a></td><td>MenA conjugate vaccine (5µg)</td><td>Monovalent serogroup A (MenA) conjugate vaccine (5µg) vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE70<a name=\"IMMZ.D1-DE70\"> </a></td><td>Monovalent MenC conjugate</td><td>Monovalent MenC conjugate vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE71<a name=\"IMMZ.D1-DE71\"> </a></td><td>Quadrivalent conjugate</td><td>Quadrivalent conjugate (A,C,W135,Y-D and A,C,W135,Y-CRM) vaccines</td></tr><tr><td style=\"white-space:nowrap\">DE97<a name=\"IMMZ.D1-DE97\"> </a></td><td>Polysaccharide vaccine</td><td>Polysaccharide vaccines not including polysaccharide-protein conjugate vaccines</td></tr><tr><td style=\"white-space:nowrap\">DE72<a name=\"IMMZ.D1-DE72\"> </a></td><td>Age in months when client received first meningococcal dose</td><td>The age in months when client received their first meningococcal dose</td></tr><tr><td style=\"white-space:nowrap\">DE73<a name=\"IMMZ.D1-DE73\"> </a></td><td>Type of hepatitis A dose</td><td>The type of hepatitis A vaccine dose administered to the client</td></tr><tr><td style=\"white-space:nowrap\">DE74<a name=\"IMMZ.D1-DE74\"> </a></td><td>Live attenuated hepatitis A vaccine</td><td>Live attenuated hepatitis A vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE75<a name=\"IMMZ.D1-DE75\"> </a></td><td>Inactivated hepatitis A vaccine</td><td>Inactivated hepatitis A vaccine</td></tr><tr><td style=\"white-space:nowrap\">DE76<a name=\"IMMZ.D1-DE76\"> </a></td><td>VNA level</td><td>Vaccine-induced neutralizing (VNA) antibody level. It is a measured as a serum antibody concentration amount observed from the result of the concentrated, purified cell culture and embryonated egg-based rabies vaccines (CCEEV)</td></tr><tr><td style=\"white-space:nowrap\">DE98<a name=\"IMMZ.D1-DE98\"> </a></td><td>Risk of occupational exposure to rabies virus</td><td>Professional at risk of occupational exposure to rabies virus, particularly animal health-care workers. Also considered for medical professionals who regularly provide care to persons with rabies.</td></tr><tr><td style=\"white-space:nowrap\">DE77<a name=\"IMMZ.D1-DE77\"> </a></td><td>Seronegative for dengue</td><td>The client is known to be seronegative for dengue</td></tr><tr><td style=\"white-space:nowrap\">DE99<a name=\"IMMZ.D1-DE99\"> </a></td><td>Evidence of a past dengue infection</td><td>There is evidence of a past dengue infection based on an antibody test or on a documented laboratory confirmed dengue infection in the past</td></tr><tr><td style=\"white-space:nowrap\">DE19<a name=\"IMMZ.D1-DE19\"> </a></td><td>Vaccine type</td><td>Vaccine type/category that was administered or was to be administered. Any vaccine code available in the IMMZ.Z Vaccine Library list of codes applies in this data element</td></tr><tr><td style=\"white-space:nowrap\">DE20<a name=\"IMMZ.D1-DE20\"> </a></td><td>Date and time of vaccination</td><td>Represents the visit/encounter date, which is the date and time when the vaccine was administered to the client</td></tr></table></div>"},"url":"http://smart.who.int/ig/smart-immunizations/CodeSystem/IMMZ.D1","version":"0.1.0","name":"IMMZ_D1","title":"IMMZ.D1 CodeSystem for Data Elements","status":"draft","experimental":false,"date":"2024-01-19T21:33:08+05:00","publisher":"World Health Organization (WHO)","contact":[{"name":"World Health Organization (WHO)","telecom":[{"system":"url","value":"https://www.who.int"}]}],"description":"CodeSystem for IMMZ.C Data Elements","jurisdiction":[{"coding":[{"system":"http://unstats.un.org/unsd/methods/m49/m49.htm","code":"001"}]}],"caseSensitive":false,"content":"complete","count":59,"concept":[{"code":"DE80","display":"Dose 0 administered","definition":"Indicates if the client has received a birth dose and/or a zero dose"},{"code":"DE95","display":"Booster dose administered","definition":"Indicates if the client has received a booster dose and/or a supplementary dose"},{"code":"DE8","display":"Completed the primary vaccination series","definition":"Indicates if the client has completed the primary vaccination series of a product/antigen. If the client has not yet completed their primary series, it means they may be expected to receive more doses to complete their vaccination regimen for the respective product/antigen."},{"code":"DE81","display":"Date when primary vaccination series was completed","definition":"The date when the client completed the primary vaccination series (per product/antigen)"},{"code":"DE10","display":"HIV status","definition":"The current human immunodeficiency virus (HIV) status of the client"},{"code":"DE11","display":"HIV-positive","definition":"The client is known to be HIV positive"},{"code":"DE12","display":"HIV-negative","definition":"The client is known to be HIV negative"},{"code":"DE13","display":"Unknown","definition":"The client's HIV status is unknown"},{"code":"DE15","display":"Preterm birth","definition":"The infant was preterm; the mother gave birth to the infant when gestational age was less than 37 weeks"},{"code":"DE16","display":"Immunocompromised","definition":"The client is known to be immunocompromised. This means the client has a weakened immune system and having a reduced ability to fight infections and other diseases"},{"code":"DE17","display":"Currently on ART","definition":"The client is currently receiving antiretroviral therapy (ART)"},{"code":"DE84","display":"Type of TB infection test performed","definition":"The type of TB infection test performed"},{"code":"DE85","display":"IGRA","definition":"Interferon-gamma release assay (IGRA)"},{"code":"DE86","display":"TST","definition":"Tuberculin skin test (TST)"},{"code":"DE87","display":"TB infection test result","definition":"Records the result of the TB infection test"},{"code":"DE88","display":"Positive","definition":"Test result was positive"},{"code":"DE89","display":"Negative","definition":"Test result was negative"},{"code":"DE93","display":"Immunologically stable","definition":"The client is living with HIV and is immunologically stable with CD4 count or percentage above a minimum as defined in the HIV guidelines"},{"code":"DE94","display":"Clinically well","definition":"The client is living with HIV and is clinically well, as defined in HIV guidelines and WHO clinical staging"},{"code":"DE29","display":"Birth weight in grams","definition":"Represents the client's birth weight value measures in grams"},{"code":"DE35","display":"Type of polio dose","definition":"The type of the polio vaccine dose administered to the client"},{"code":"DE36","display":"IPV","definition":"Inactivated poliovirus vaccine (IPV)"},{"code":"DE37","display":"bOPV","definition":"Bivalent oral poliovirus vaccine (bOPV)"},{"code":"DE38","display":"Age in years when client received first DTP dose","definition":"The client's age in years when they received their first diphtheria-tetanus-pertussis (DTP) dose"},{"code":"DE39","display":"Age in months when client received first Hib dose","definition":"The client's age in months when they received their first Haemophilus influenzae type b (Hib) dose"},{"code":"DE92","display":"Severely immunosuppressed","definition":"The client is known to be severely immunocompromised or immunosuppressed"},{"code":"DE49","display":"ART start date","definition":"The date on which the client started or restarted antiretroviral therapy (ART)"},{"code":"DE96","display":"High risk of pneumococcal infection","definition":"The client is at high risk for pneumococcal infection because of underlying medical conditions (i.e. HIV infection or sickle-cell disease)"},{"code":"DE52","display":"Type of JE dose","definition":"The type of Japanese encephalitis (JE) vaccine dose administered to the client"},{"code":"DE53","display":"Inactivated Vero cell-derived vaccine","definition":"Inactivated Vero cell-derived Japanese encephalitis (JE) vaccine type"},{"code":"DE54","display":"Live attenuated vaccine","definition":"Live attenuated Japanese encephalitis (JE) vaccine type"},{"code":"DE55","display":"Live recombinant vaccine","definition":"Live recombinant Japanese encephalitis (JE) vaccine type"},{"code":"DE56","display":"Type of TBE dose","definition":"The type of tick-borne encephalitis (TBE) vaccine dose administered"},{"code":"DE57","display":"FSME-Immun","definition":"FSME-Immun vaccine product, which is an inactivated whole-virus vaccine for tick-borne encephalitis (TBE)"},{"code":"DE58","display":"Encepur","definition":"Encepur vaccine product, which is an inactivated viral vaccine for tick-borne encephalitis (TBE)"},{"code":"DE59","display":"TBE-Moscow","definition":"TBE-Moscow vaccine product, which is a vaccine for tick-borne encephalitis (TBE)"},{"code":"DE60","display":"EnceVir","definition":"EnceVir vaccine product, which is a vaccine for tick-borne encephalitis (TBE)"},{"code":"DE61","display":"Type of typhoid dose","definition":"The type of typhoid vaccine dose administered to the client"},{"code":"DE62","display":"Typbar-TCV","definition":"Typbar-TCV vaccine"},{"code":"DE63","display":"ViPS","definition":"Vi polysaccharide (ViPS) vaccine"},{"code":"DE64","display":"Ty21a","definition":"Ty21a vaccine"},{"code":"DE65","display":"Type of cholera dose","definition":"The type of cholera vaccine dose administered to the client"},{"code":"DE66","display":"WC vaccine","definition":"Killed whole cell (WC) only cholera vaccine"},{"code":"DE67","display":"WC-rBS vaccine","definition":"Vaccine contains a mixture of the recombinant B subunit (rBS) of cholera toxin plus killed whole cell (WC)"},{"code":"DE68","display":"Type of meningococcal dose","definition":"The type of meningococcal vaccine dose administered to the client"},{"code":"DE69","display":"MenA conjugate vaccine (5µg)","definition":"Monovalent serogroup A (MenA) conjugate vaccine (5µg) vaccine"},{"code":"DE70","display":"Monovalent MenC conjugate","definition":"Monovalent MenC conjugate vaccine"},{"code":"DE71","display":"Quadrivalent conjugate","definition":"Quadrivalent conjugate (A,C,W135,Y-D and A,C,W135,Y-CRM) vaccines"},{"code":"DE97","display":"Polysaccharide vaccine","definition":"Polysaccharide vaccines not including polysaccharide-protein conjugate vaccines"},{"code":"DE72","display":"Age in months when client received first meningococcal dose","definition":"The age in months when client received their first meningococcal dose"},{"code":"DE73","display":"Type of hepatitis A dose","definition":"The type of hepatitis A vaccine dose administered to the client"},{"code":"DE74","display":"Live attenuated hepatitis A vaccine","definition":"Live attenuated hepatitis A vaccine"},{"code":"DE75","display":"Inactivated hepatitis A vaccine","definition":"Inactivated hepatitis A vaccine"},{"code":"DE76","display":"VNA level","definition":"Vaccine-induced neutralizing (VNA) antibody level. It is a measured as a serum antibody concentration amount observed from the result of the concentrated, purified cell culture and embryonated egg-based rabies vaccines (CCEEV)"},{"code":"DE98","display":"Risk of occupational exposure to rabies virus","definition":"Professional at risk of occupational exposure to rabies virus, particularly animal health-care workers. Also considered for medical professionals who regularly provide care to persons with rabies."},{"code":"DE77","display":"Seronegative for dengue","definition":"The client is known to be seronegative for dengue"},{"code":"DE99","display":"Evidence of a past dengue infection","definition":"There is evidence of a past dengue infection based on an antibody test or on a documented laboratory confirmed dengue infection in the past"},{"code":"DE19","display":"Vaccine type","definition":"Vaccine type/category that was administered or was to be administered. Any vaccine code available in the IMMZ.Z Vaccine Library list of codes applies in this data element"},{"code":"DE20","display":"Date and time of vaccination","definition":"Represents the visit/encounter date, which is the date and time when the vaccine was administered to the client"}]}